Favrille Announces FDA Allowance Of Investigational New Drug Application For FAV-201, A Patient-Specific Immunotherapy (Medical News Today)
Favrille, Inc. (Nasdaq:FVRL), a biopharmaceutical company developing patient-specificimmunotherapies for the treatment of cancer, announced today that itselectronic Investigational New Drug (IND) application for FAV-201, apatient-specific immunotherapy for the treatment of T-cell lymphoma, hasbeen cleared by the U.S. Food & Drug Administration (FDA). [click link for full article]

Baxter Receives Tentative FDA Approvals For Ondansetron Injection In Vials And Premix Containers (RedNova)
DEERFIELD, Ill., June 15 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced that it has received tentative approvals from the U.S.

Baxter Receives Tentative FDA Approvals For Ondansetron Injection In Vials And Premix Containers (Medical News Today)
Baxter HealthcareCorporation today announced that it has received tentative approvals fromthe U.S. Food and Drug Administration (FDA) for Ondansetron Injection USP,including the first tentative approval for a premix version ofGlaxoSmithKline's Zofran(R), which is used for the prevention of nausea andvomiting. [click link for full article]